Xeris Biopharma Holdings (XERS) EBT (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported EBT for 7 consecutive years, with -$31.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 1513.12% year-over-year to -$31.1 million; the trailing twelve-month figure through Jun 2026 stood at -$17.2 million (up 51.41% YoY), and the FY2025 full-year result was $554000.0, up 100.97% from the prior year.
• EBT eased to -$31.1 million in Q2 2026 per XERS's latest filing, from $2.2 million in the prior quarter.
• Across five years, EBT topped out at $11.1 million in Q4 2025 and bottomed at -$34.1 million in Q1 2022.
• Historically, EBT has averaged -$13.6 million across 5 years, with a median of -$13.9 million in 2023.
• The sharpest annual moves came in 2025 and 2026: EBT soared 316.72% in 2025, then tumbled 1513.12% in 2026.
• Over 5 years, EBT stood at -$13.3 million in 2022, then declined by 2.7% to -$13.6 million in 2023, then jumped by 62.48% to -$5.1 million in 2024, then jumped by 316.72% to $11.1 million in 2025, then tumbled by 380.67% to -$31.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$31.1 million, $2.2 million, and $11.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.